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ABSTRACT
Background/Aims: Endoscopic submucosal dissection has been widely accepted. At present, the number of
antiplatelet (APT) users has been growing. Moreover, because of high risks of thromboembolism, some patients
need to continuously receive APT agents. The relationship between hemorrhage and continuous therapy with
low-dose aspirin (LDA) remains controversial.
Materials and Methods: A systematic search was conducted; studies were screened out- if data of no-anticoagulant/APT drugs use and interrupted and continued-LDA use were reported separately. The Newcastle-scale
was chosen to assess the quality of the included studies. Review Manager 5.2 was used for quality assessment
statistical analysis, and the odd ratio (OR) and 95% confidence interval (CI) were calculated.
Results: Pooled data suggested a significantly higher bleeding ratio in the LDA-continued group compared to
both the LDA-interrupted group (OR=2.05, 95% CI=1.05-3.99) and no-anticoagulant/APT group (OR=2.89, 95%
CI=1.86-4.47). However, the LDA-interrupted group did not differ significantly from the no-anticoagulant/APT
group. The en bloc resection rates of the LDA-continued group versus the LDA-interrupted group, the LDAcontinued group versus no-anticoagulant/APT group, and the LDA-interrupted group versus the no-anticoagulant/APT group were similar (OR=0.82, 95% CI=0.21-3.24, p=0.78; OR=0.80, 95% CI=0.24-2.65, p=0.71; OR=1.41,
95% CI=0.38-5.24, p=0.60, respectively).
Conclusion: There is an extremely high ratio of bleeding in the LDA-continued group compared to both the
LDA-interrupted group and no-anticoagulant/APT group. All groups had similar ratios of en bloc resection.
Keywords: Endoscopic submucosal dissection, gastrointestinal neoplasms, antiplatelet agents, gastroenterological hemorrhage, meta-analysis
INTRODUCTION
Endoscopic submucosal dissection (ESD) is a normal
therapeutic technology that allows en bloc excision
and complete excision for early gastrointestinal cancers
or dysplastic lesions (1-6). One of the complications of
gastrointestinal ESD is postoperative hemorrhaging.
Some researchers have shown that the average
rate of post-ESD bleeding of colorectal carcinoma
is 1.8% (5). However, in gastric carcinoma, the rate of
post-ESD bleeding ranged from 5.3% to 15.6% (7).
The use of antiplatelet (APT) agents has a far-reaching
impact on gastrointestinal post-ESD bleeding (7-9). Al-

though some researchers believe that patients on APT
agents or anticoagulants may increase the chance of
gastrointestinal post-ESD bleeding, others have shown
the opposite result (8-11). Low-dose aspirin (LDA) is
commonly used for cerebrovascular and cardiovascular
diseases (12-14). At present, several international organizations in the USA and Europe have made an effort in
drafting guidelines to manage the use of anticoagulant
and APT agents for patients during and after ESD (1517). In Japan, the guidelines recommend perioperative
continuation of LDA for patients undergoing ESD procedures that have high bleeding risks (18). However, the
data and literature are limited. Whether the continuous
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use of LDA increases the bleeding risk after gastrointestinal
ESD remains controversial; this issue needs to be resolved (19).
Therefore, a systematic search on the databases and a metaanalysis were conducted to determine whether patients undergoing ESD for gastrointestinal tumors are at risk of bleeding
after continued use of LDA.
MATERIALS AND METHODS
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Search Method and Methodological Quality Assessment
Ethics committee approval was obtained and the study was
in adherence with the Declaration of Helsinki. We do not have
the informed consent. Because we do not use the original data
from patients, we just summary the data from others published
literatures. Our search analyzed data from PubMed and Cochrane library updated in October 2015 and included a matching essay on the effect of aspirin after gastrointestinal ESD. The
algorithms used in the search included “Aspirin” [Mesh] OR
“Platelet Aggregation Inhibitors” [Mesh] OR “Dalteparin” [Mesh]
AND “Stomach Neoplasms” [Mesh] OR “Colorectal Neoplasms”
[Mesh] AND “ESD.” The references in the searchable results were
selected manually. The data were obtained by two separated
evaluators.
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analysis (10,11,24-26) (Figure 1). The Newcastle-Ottawa scale
was used to assess the quality of the included studies (Table 1).
Detailed Information of the Selected Studies
The five selected publications included four historical cohort
studies and one case-control study (10,11,24-26). Four studies
involved gastric cancer and one involved colorectal cancer;
four studies described tumor location and tumor size and two
mentioned operation time and rate of perforation; all the studies were published from 2012 to 2015 (10,11,24,26) (Table 2).
The information on age was introduced in five publications.
The median age of the patients in the no-anticoagulant/APT
group, LDA-continued group, and LDA-interrupted group
ranged from 61.6 to 67 years, 66.8 to 75.9 years and 64.5 to 72.7
years, respectively. The ratios of males to females in the five papers were as follows: 1627 to 671 in the no-anticoagulant/APT

Potentially relevant literature
identified and screened for
retrieval (n= 305)

Abstracts excluded because of
not relevant, letter, review
(n= 283)

The collected literature compared the risk of bleeding from
continued-LDA use or from interrupted-LDA use with the risk
from no-LDA use. Patients diagnosed with cancer or precancerous lesions were included, and reviews, case reports, abstracts,
and letters were excluded. The Newcastle-Ottawa scale was
used to assess the quality of the included studies and the funnel plot scale to assess the publication bias (20,21).

Articles retrieved for full-text
evaluation (n= 22)

Articles excluded because of
non-comparative study (n= 12)
or other than endoscopic
submucosal dissection (n= 5)

Data Extraction
The patients’ basic information incorporated the main APT
agents, size and location of the lesions, length of the procedures, en bloc resection, bleeding, and perforation rate. The location of lesions and bleeding after ESD were defined according to the literature (22,23).
Statistical Analysis
For all data, we computed the odds ratio (OR) and 95% confidence interval (CI). The Collaboration’s RevMan 5.3 software
(The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark) was used for statistical analysis. The forest
plot was used to confirm the rates of en bloc resection and
bleeding in each group. Chi square and I2 tests were used to
examine the statistical heterogeneity. If I2>50% and p<0.1, the
random effects model was chosen; if there was no heterogeneity, the fixed-effects model was applied.
RESULTS
Assessment of the Selected Studies
A total of 305 relevant papers were collected using the key
search words. Five full-text studies were chosen for the final
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Articles suitable for metaanalysis (n= 5)

Figure 1. The PRISMA flowchart of literature review
Table 1. Quality assessment of bias in the included studies
		Outcome/
Selection
exposure
Author

1

2

Sanomura et al. (24)

★

Ninomiya et al. (11)

3

4

Comparability

1

★

★

★★

★

★

★

★

★

★

Lim et al. (10)

★

★

★

★

★

★ ★

Matsumura et al. (25)

★

★

★★

★

★

Cho et al. (26)

★

★		 ★

★

2

3

★		

Quality assessment of bias in the included studies was evaluated based on the Newcastle-Ottawa quality assessment scale
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Table 2. Details of included studies

Operation
En bloc
Perforation
time (min) resection (n)
(n)

Sanomura
et al. (24)

Historical
Early
LDAAspirin,
cohort
gastric
continued
ticlopidine,
study
cancer group (n=28) clopidogre,
				
cilostazol

75.9±8.2

20/5

8/4/16

18.3

49.6

28

0

			
LDA-		
			interrupted
			
group (n=66)

72.7±9.1

44/12

11/20/35

16.6

45.3

63

3

Ninomiya
et al. (11)

67.0±11.1

19/9

15/8/8

35.4±18.9

83.6±59.0

30

2

			
LDA-		
			interrupted
			
group (n=13)

66.9±11.2

12/1

5/1/7

35.7±18.9

86.3±63.8

13

1

			
No-		
			anticoagulant/
			 APT group (n=565)

67.0±11.1 379/163 236/120/209

35.5±18.8

85.2±63.5

538

28

20/56/96

47.8±15.02

-

-

-

15/21/66

45.9±11.25

-

-

-

61.61±9.321 923/394 116/428/773 45.5±13.91

-

-

-

Lim
et al. (10)

Historical Colorectal
LDAAspirin,
cohort
tumors
continued
clopidogre,
study		
group (n=31) Ticlopidine

Historical
cohort
study

Early
LDAAspirin,
67.60±7.807 135/37
gastric
continued
clopidogre,
cancer group (n=172) cilostazol

			
LDA-		
			interrupted
			
group (n=102)
			No			anticoagulant/
			 APT group (n=1317)		
Matsumura CaseGastric
et al. (25)
control
cancer
study		

-

-

-

-

-

-

-

			
LDA-					interrupted
			
group (n=41)

-

-

-

-

-

-

66.8±9.6

16/3

12/3/4

15

-

17

-

			
LDA-		
			interrupted
			
group (n=56)

64.5±8.8

44/12

43/11/2

15

-

54

-

			
No-		
			anticoagulant/
			 APT group (n=439)

61.7±9.3

325/114

330/73/36

15

-

417

-

Cho
et al. (26)

Historical
Gastric
cohort
cancer
study		

LDAcontinued
group (n=21)

Aspirin

66.45±7.341 85/17

LDAAspirin,
continued
clopidogre,
group (n=19) other APTs
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Patient ages,		 Tumor location Tumor
					
mean±SD		
(U/M/L or
size
Study		
Study
Main APT or median Male/
right/left/
(mm,
Author
design
Disease
groups
agents
(range) Female
rectum)
median)

SD: standard deviation; L: lower; M: middle; U: upper; LDA: low-dose aspirin; APT: antiplatelet

group, 190 to 54 in the LDA-continued group, and 185 to 42 in
the LDA-interrupted group.
Bleeding Complication
Five studies with data available on bleeding included 271 patients who received LDA-continued treatment for thromboembolic events before and after ESD therapies; they also included 278 controls who received LDA-interrupted treatment

(10,11,24-26). The average incidence of bleeding in the LDAcontinued group was up to 11.8% but was 5.4% in the LDA-interrupted group. One study introduced a higher rate of bleeding in the LDA-continued group, whereas the remaining four
studies indicated no significant difference in the proportion
of bleeding. We chose the fixed-effects model for pool analysis because of the low heterogeneity among the five studies
(p=0.54; I2=0%) (19,11,24-26). The result illustrated that there
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a
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b

c

d

e

f

Figure 2. a-f. Forest plots were used to verify the relative effects of en bloc resection and adverse events of bleeding in each group. Results regarding the
rate of post-ESD bleeding (a-c) and rate of en bloc resection are shown (d-f )
ESD: endoscopic submucosal dissection; CI: confidence interval; W: weight; OR: odds ratio; LDA: low-dose aspirin; APT: antiplatelet
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was a significantly higher bleeding ratio in the LDA-continued group than in the LDA-interrupted group (OR=2.05, 95%
CI=1.05-3.99, p=0.04; Figure 2a). According to the results of the
funnel plots, there was no publication bias (Figure 3a).
Three of the trials with data available on bleeding included
171 patients who perioperatively received LDA-interrupted
treatment and 2321 controls who did not use anticoagulant/
APT agents (10,11,26). In the no-anticoagulant/APT group,
the incidence of bleeding was 4.8%, but was 5.8% in the LDAinterrupted group. The fixed-effects model was used for pool

analysis because of the low heterogeneity among the three
studies (p=0.43; I2=0%). There was no significant difference between the bleeding ratio in the LDA-interrupted group and noanticoagulant/APT group (OR=1.31, 95% CI=0.67-2.56, p=0.43;
Figure 2b). This result suggests that the incidence of bleeding
in the LDA-interrupted group was similar to that in the no-anticoagulant/APT group. According to the result of the funnel
plots, there was no publication bias (Figure 3b).
Data on bleeding were available for three trials, and they included 222 patients who received continued-LDA treatment
b

c

d

e

f

Original Article

a

Figure 3. a-f. Funnel plots were used to obtain evidence of publication bias. The results regarding the rate of post-ESD bleeding (a-c) and the rate of en
bloc resection (d-f ) are shown
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for thromboembolic events during the period of ESD therapies
and 2321 controls who did not use anticoagulant/APT treatment (10,11,26). The incidence of bleeding in the LDA-continued group was up to 13.1%, but was 4.8% in the no-anticoagulant/APT group. Significant heterogeneity did not exist among
those publications (p=0.22; I2=34%); hence, the fixed-effects
model was chosen for pool analysis. The result illustrated that
there was a significantly higher bleeding ratio in the LDA-continued group compared to the no-anticoagulant/APT group
(OR=2.89, 95% CI=1.86-4.47, p<0.00001; Figure 2c). According
to the result of the funnel plots, there was no publication bias
(Figure 3c).

Original Article

En Bloc Resection
The incidence of en bloc resection was reported in three studies (11,24,26). These reported 213 lesions (n=78 in the LDAcontinued group and n=135 in the LDA-interrupted group).
Significant heterogeneity did not exist among studies (p=0.44;
I2=0 %); therefore, the fixed-effects model was used for pool
analysis. No significant difference was found in the en bloc resection rate between the continued-LDA group and the interrupted-LDA group (OR=0.82, 95% CI=0.21-3.24, p=0.78; Figure
2d). According to the result of the funnel plots, there was no
publication bias (Figure 3d).
Two reports compared the incidence of en bloc resection between the continued-LDA group and the no-anticoagulant/
APT group (11,26). The fixed-effects model was used for pool
analysis because of the low heterogeneity between the two
studies (p 0.34; I2=0%). There was no significant difference in
the en bloc resection ratio between LDA-continued group
and no-anticoagulant/APT group (OR=0.80, 95% CI=0.242.65, p=0.71; Figure 2e). This result suggests that the incidence of en bloc resection of the LDA-continued group was
similar to that of the no-anticoagulant/APT group. According
to the result of the funnel plots, there was no publication bias
(Figure 3e).
Two reports with data available on en bloc resection included
patients who perioperatively received LDA-interrupted treatment and who did not use anticoagulant/APT agents (11,26).
The fixed-effects model was used for pool analysis because
of the low heterogeneity between the two studies (p=0.98;
I2=0%). There was no significant difference in the en bloc resection ratio between LDA-continued group and no-anticoagulant/APT group (OR=1.41, 95% CI=0.38-5.24, p=0.60); Figure 2f ).
This result indicates that the incidence of en bloc resection of
the LDA-continued group was similar to that of the no-anticoagulant/APT group. According to the result of the funnel plots,
there was no publication bias (Figure 3f ).
DISCUSSION
Endoscopic submucosal dissection is an advanced, complex
endoscopic technique that is currently used for early gastrointestinal cancers or dysplastic lesions. Bleeding is a major
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procedural complication during ESD. Although the chance
of bleeding after ESD is low, particular caution is necessary because some delayed bleeding could result in severe
adverse events, such as cardiovascular events and hypovolemic shock. At present, the users of APT drugs have been
growing because of prevention of thrombotic complications.
Moreover, some patients cannot interrupt anticoagulants
because of the high risk of thromboembolism. Clinical trials
have shown that long-term use of anticoagulants decreases
the risk of cardiovascular events, but at the expense of an increased risk of delayed bleeding. However, there are no published multicenter studies showing the relation between APT
agents (such as aspirin) and post-ESD bleeding; there are only
a few expert opinions and one single-center retrospective
study. Therefore, this meta-analysis was devised to investigate
whether continuous LDA use could increase the risk of postESD bleeding and to obtain evidence for APT users based on
evidence-based medicine.
The meta-analysis conclusively shows that the incidence of
post-ESD bleeding in gastrointestinal tract has no difference
between patients with no-LDA use and those with interrupted-LDA use; however, the incidence is higher in continuedLDA users. In contrast, continued-LDA use, interrupted-LDA
use, and the absence of LDA use show equal rates of en bloc
resection.
Regarding connection between the use of antithrombotic
drugs and the hazard for post-ESD bleeding, the results are
complicated. Some researchers have shown that patients are
at higher risk of bleeding during or after ESD with continuous
LDA use (9,26,27). Others have shown the opposite result, indicating that using the LDA continuously does not increase the
hazard of bleeding (10,24). We conducted a comprehensive
and multicenter literature search and found that using LDA
continuously may enhance the risk of bleeding, corresponding
to the reported observations of Cho et al. (26).
At present, some studies indicate that using aspirin may lead to
post-ESD bleeding, but it does not increase long-term morbidity or mortality; patients at high risk of cardiovascular and cerebrovascular complications need to take aspirin continuously
(26). Among the five articles included in this meta-analysis, two
reported complications of thromboembolism when patients
stopped taking aspirin (10,24). One study reported that two
patients experienced cerebrovascular infarction and two experienced acute myocardial infarction when LDA was stopped
in patients before ESD (24). In the Lim JH study, after discontinuing the use of aspirin for 5 days, a patient experienced serious cerebral infarction and atrial fibrillation (10). Moreover, a
multicenter survey showed that among the Japanese patients,
incidence of cerebral infarctions was higher than that of severe
post-ESD bleeding upon discontinuation of aspirin (28). The
aforementioned studies indicate that the discontinuation of
aspirin intake may lead to some serious events compared to its
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Some studies reported that bleeding was associated with lesion size and tumor location; for example, the hazard of postESD bleeding was higher when the lesions were located in the
cecum, but it was difficult to stratify patients by these factors
in our meta-analysis (31,32). There were also some unanswered
questions regarding the bleeding of post-ESD and aspirin use.
A recent study showed that the ratio of bleeding after ESD was
higher in the anticoagulant agents group than in the nonanticoagulants agent group, 23.3% and 2%, respectively; however,
the study did not examine the methods of drug use or which
antithrombotic drugs may increase the rate of bleeding (27).
In another study, the use of heparin caused a higher risk of delayed bleeding after gastric ESD (33). Takeuchi found that combining LDA with warfarin and longer ESD operations increased
the rate of post-ESD bleeding (27). Moreover, Satoshi showed
that taking thienopyridine derivatives with aspirin increased
the hazard of bleeding after ESD, particularly in gastric ESD (34).
These issues warrant further studies.
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continuation. The main reason for this phenomenon is that a
patient who experienced cardiovascular and atherothrombotic diseases may be more likely at severe risk of acute ischemic
events with the cessation of aspirin. Therefore, an individualized
approach that fully considers patients’ risk and benefit should
be applied (29). Aspirin use should be stopped when a person
has a low risk for thromboembolic disease. However, when a
person has a high risk for thromboembolism, continuous aspirin use should be advised, despite the high risk of post-ESD
bleeding. This is because thromboembolic events are more serious than post-ESD bleeding, which can decrease a patient’s
quality of life (26). ESD has an advantage over endoscopic mucosal resection for en bloc resection (30). With regard to the
result of gastrointestinal ESD, the en bloc resection rates were
quite high in all three groups included in this meta-analysis,
suggesting no effect of aspirin on en bloc resection.
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